Latest Breaking News On - தீர்ப்பியல்ட் மேலாண்மை - Page 7 : comparemela.com
Guilford s Hyperfine goes public in SPAC deal valued at $580M | Hartford Business Journal
hartfordbusiness.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hartfordbusiness.com Daily Mail and Mail on Sunday newspapers.
Around the nation: HHS watchdog wants stronger cybersecurity requirements for hospitals
advisory.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from advisory.com Daily Mail and Mail on Sunday newspapers.
Published: Jul 02, 2021 By Alex Keown
OcuTerra Therapeutics – David J. Tanzer was named Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs for Boston-based OcuTerra. Prior to joining OcuTerra, Tanzer served as Global Executive Medical Director in the Novartis ophthalmology franchise. Before that, he served as the CMO at Abbott Medical Optics. He also led the Navy Refractive Surgery Program in San Diego, participating as principal or co-investigator in over 50 clinical studies.
Delix Therapeutics – David E. Olson, co-founder and Chief Scientific Officer of Delix Therapeutics, was an Innovator of the Year award winner at UC Davis. Olson is an assistant professor in the Department of Chemistry and Department of Biochemistry and Molecular Medicine at UC Davis. He was named an Innovator of the Year for his groundbreaking work with non-hallucinatory psychedelics that have the potential to make “measurable societal impact.” Olson and his
Identification of an Altered Matrix Signature in Kidney Aging and Disease
asnjournals.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asnjournals.org Daily Mail and Mail on Sunday newspapers.
July 1, 2021
July 1, 2021 | Insilico Medicine closes a Series C for AI-powered drug discovery, while other investments fuel remote access labs, natural products, high throughput screening, and more.
$550M: VC Fund for Therapeutics for Unmet Needs
venBio has announced the closing of venBio Global Strategic Fund IV, LP (“venBio Fund IV”), its fourth life sciences venture capital fund, exceeding its target and closing on approximately $550 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds. Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals